

## PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

August 19<sup>th</sup>, 2022

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

| Drug/Class                     | Effective Date | Overview  |
|--------------------------------|----------------|---|
| Stelara                        | 9/1/2022       | Updating PA form for Ulcerative Colitis continuation criteria to account for IV formulation                         |
| Skyrizi                        | 9/1/2022       | Adding new formulation to the formulary with PA and adding Crohn's disease indication to PA form                    |
| Imcivree                       | 9/1/2022       | Adding new indication to PA form for obesity due to Bardet-Biedl syndrome (BBS)                                     |
| Tafinlar/Mekinist              | 9/1/2022       | Adding new indication to PA form for solid tumors with the BRAF V600E mutation                                      |
| CGMs (Dexcom, Freestyle Libre) | 9/1/2022       | Removing three provider attestation-related criteria from PA form   |
| Jynarque                       | 10/15/2022     | Updating PA criteria to align with recent guideline updates on patient age and disease progression                  |
| Xultophy                       | 9/1/2022       | Updating PA approval duration to lifetime   |
| Soliqua                        | 9/1/2022       | Updating PA approval duration to lifetime   |
| Nerlynx                        | 9/1/2022       | Changing 'high-risk of recurrence' PA criteria to simply a provider attestation and adding continuation PA criteria |
| pyrimethamine                  | 10/15/2022     | Updating PA criteria to align with guidelines, which requires use with leucovorin for certain diagnoses             |
| Pomalyst                       | 9/1/2022       | Adding new indication to PA form for Kaposi sarcoma   |
| Rubraca                        | 10/15/2022     | Removing withdrawn indication from PA form for recurrent BRCA mutated advanced ovarian cancer                       |